Yehiel Tal on biotechnology
From Amplifying Scientific Innovation Podcast with Mr. Yehiel Tal, CEO@collplantbio8262 · · The Sophia Consulting Firm
“We are the only company that can solve this problem with our collagen — our collagen is produced in plants, it's virgin recombinant human collagen and it does not elicit an immune response, which is very important particularly when you make large constructs for transplants.”
On , Yehiel Tal, CEO at CollPlant Biotechnologies, spoke about biotechnology during Amplifying Scientific Innovation Podcast with Mr. Yehiel Tal, CEO@collplantbio8262 on The Sophia Consulting Firm.
About Yehiel Tal
In a March 2021 podcast interview, Yehiel Tal, CEO of CollPlant Biotechnologies, discussed the company's recombinant human collagen (rhCollagen) technology platform. Tal stated that the company's collagen is "produced in plants" and is "virgin recombinant human collagen" that "does not elicit an immune response," which he described as important for making large constructs for transplants. He also defined scientific innovation as being effective when properly planned. Tal described several operational changes at CollPlant during the COVID-19 pandemic. He said the company decided to pay full salaries to all employees, which he said motivated staff and contributed to the company. He also noted that the company adopted remote work, enhanced its use of social media for investor and collaborator positioning, and used platforms like LinkedIn and virtual university events for recruitment. Tal advised other CEOs to plan ahead, build flexible company structures, and maintain multiple suppliers and strategic collaborators for critical items.